---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-036095"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2024-11-25T23:59:59+00:00"
generated_at: "2026-05-29T19:01:06.753542+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Eton Pharmaceuticals acquires U.S. rights to Amglidia (glyburide oral suspension) for neonatal diabetes

## Summary
- No upfront payment; up to $2.35M in milestone payments plus 14% royalty on net sales.
- Amglidia approved by EMA in 2018, has U.S. FDA Orphan Drug Designation.
- Targets neonatal diabetes, a rare condition affecting ~300 U.S. patients with no FDA-approved oral treatment.
- Eton plans FDA meeting in Q1 2025 and expects NDA submission in 2026.
- Eton can terminate within 30 days of FDA meeting minutes without milestone liability.

## SEC filing metadata
- accession: 0001437749-24-036095
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2024-11-25T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774924036095/0001437749-24-036095-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774924036095/eton20241117_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-036095
- JSON: https://secwatch.observer/filing/0001437749-24-036095.json
- Plain text: https://secwatch.observer/filing/0001437749-24-036095.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.